Which agents could potentially lower testosterone levels in prostate cancer treatment?

In the context of prostate cancer treatment, lowering testosterone levels is crucial because testosterone can promote the growth of prostate cancer cells. LHRH agonists, such as leuprolide or goserelin, work by reducing the production of testosterone from the testes. They do this by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which leads to a temporary increase in testosterone production followed by a feedback inhibition that ultimately lowers testosterone levels to castrate levels.

Aromatase inhibitors also contribute to reducing estrogen levels, which can lead to a decrease in testosterone levels indirectly. Estrogen has a feedback effect on the hypothalamus and pituitary, and by reducing estrogen levels, aromatase inhibitors can also lower the levels of testosterone.

Therefore, both LHRH agonists and aromatase inhibitors are effective in potentially lowering testosterone levels as part of prostate cancer treatment strategies, making the option stating that both of these agents could lower testosterone the most appropriate choice.